- CA$175.98m
- CA$161.06m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 45.9 | ||
Price to Tang. Book | 49.33 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | n/a | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -957.1% | ||
Return on Equity | -183.58% | ||
Operating Margin | n/a |
Financial Summary
Year End 31st Oct | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | CA$m | n/a | n/a | n/a | n/a | n/a | 13.33 | n/a | n/a |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology lead asset, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases.
Directors
- Frank Holler NEC (64)
- Philip Toleikis PRE
- David Swetlow CFO
- Delfina Siroen OTH
- Mohammad Azab IND (65)
- Jeffrey Bacha IND (51)
- Deborah Brown IND
- James Parsons IND (55)
- Last Annual
- October 31st, 2023
- Last Interim
- January 31st, 2024
- Incorporated
- November 1st, 2001
- Public Since
- April 15th, 1999
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Toronto Stock Exchange
- Shares in Issue
- 303,407,686
- Address
- 700 Collip Circle, Ste 114, LONDON, N6G 4X8
- Web
- https://www.sernova.com/
- Phone
- +1 5198585126
- Contact
- Chris Barnes
- Auditors
- KPMG LLP
Upcoming Events for SVA
Q2 2024 Sernova Corp Earnings Release
Q3 2024 Sernova Corp Earnings Release
Similar to SVA
Bausch + Lomb
Toronto Stock Exchange
Hamilton Thorne
Toronto Stock Exchange
Profound Medical
Toronto Stock Exchange
Titan Medical
Toronto Stock Exchange
Vitalhub
Toronto Stock Exchange
FAQ
As of Today at 18:19 UTC, shares in Sernova are trading at CA$0.58. This share price information is delayed by 15 minutes.
Shares in Sernova last closed at CA$0.58 and the price had moved by -35.56% over the past 365 days. In terms of relative price strength the Sernova share price has underperformed the Toronto Stock Exchange 300 Composite Index by -42.83% over the past year.
The overall consensus recommendation for Sernova is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Sernova does not currently pay a dividend.
Sernova does not currently pay a dividend.
Sernova does not currently pay a dividend.
To buy shares in Sernova you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.58, shares in Sernova had a market capitalisation of CA$175.98m.
Here are the trading details for Sernova:
- Country of listing: Canada
- Exchange: TOR
- Ticker Symbol: SVA
Based on an overall assessment of its quality, value and momentum Sernova is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Sernova is CA$3.92. That is 575.86% above the last closing price of CA$0.58.
Analysts covering Sernova currently have a consensus Earnings Per Share (EPS) forecast of -CA$0.09 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sernova. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -32.16%.
As of the last closing price of CA$0.58, shares in Sernova were trading -22.94% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Sernova PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.58.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Sernova's management team is headed by:
- Frank Holler - NEC
- Philip Toleikis - PRE
- David Swetlow - CFO
- Delfina Siroen - OTH
- Mohammad Azab - IND
- Jeffrey Bacha - IND
- Deborah Brown - IND
- James Parsons - IND